Research Article
Nomogram for Predicting Recurrence-Free Survival in Chinese Women with Endometrial Cancer after Initial Therapy: External Validation
Table 4
Comparison of this study with previous studies of predictive models for recurrence-free survival of endometrial cancer patients.
| | | Obermair A | Bendifallah S | Ouldamer L | Wang J |
| | Number of cases | 2097 | 396 | 861 | 520 | | Recurrence-free survival | 3-year | 3-year | 3-year | 3- and 5-year | | Histologic type | I, II | I | I, II | I, II | | FIGO stage | I–III | I–III | I–III | I–IV | | Factors | | | | | | Age | Yes | Yes | Yes | — | | Histological grade | Yes | Yes | — | Yes | | FIGO stage | Yes | — | Yes | Yes | | Histologic type | Yes | — | Yes | — | | Tumor diameter ≥ 2 cm | — | Yes | — | Yes | | Myometrial invasion ≥ 50 % | — | Yes | — | — | | LVSI | Yes | Yes | Yes | — | | Peritoneal washing | Yes | — | — | Yes | | Surgical nodal staging | — | — | Yes | | | Comparison with FIGO stage | — | — | — | Superior | | 3-year internal validation | Yes (0.86) | Yes (0.74) | Yes (0.75) | Yes (0.89) | | 5-year internal validation | — | — | — | Yes (0.87) | | 3-year external validation | — | Yes (0.82) | — | Yes (0.88) | | 5-year external validation | — | — | — | Yes (0.87) |
|
|
FIGO = International Federation of Gynecology and Obstetrics; LVSI = lymphovascular space involvement.
|
